ORYZON to Regain Rights to ORY-1001 (RG6016)


• Management to Host two Web Conferences today, July 20th
    - at 10:00 am CET in Spanish and
    - at 8:30 am ET in English

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that yesterday evening Roche informed Oryzon that due to a portfolio prioritization, it has decided to discontinue its involvement in the clinical development of the investigational Lysine Specific Demethylase-1 (LSD1) inhibitor ORY-1001 (RG6016) for the treatment of patients with acute myeloid leukemia (AML) and solid tumors pursuant to the license agreement between Oryzon and Roche dated April 1st, 2014.


Click here to see the full Press Release